Tags

Type your tag names separated by a space and hit enter

Cannabinoids and cardiovascular disease: the outlook for clinical treatments.
Curr Vasc Pharmacol 2007; 5(3):175-85CV

Abstract

Cannabinoid drugs exert their effects primarily through activation of cannabinoid CB1 and CB2 receptors. Both CB1 and CB2 receptors have been implicated in a number of cardiovascular processes, including vasodilation, cardiac protection, modulation of the baroreceptor reflex in the control of systolic blood pressure, and inhibition of endothelial inflammation and the progress of atherosclerosis in a murine model. These effects are mainly mediated through central and peripheral nervous system CB1 receptors, vascular CB1 receptors and immune cell CB2 receptors. Relevant cellular effects include: the inhibition of neurotransmitter release in the nucleus tractus solitarius and in peripheral adrenergic neurons; regulation of NOS activity in vascular beds; inhibition of vascular smooth muscle cell excitability; regulation of endothelial cell migration and proliferation; and effects on immune cell proliferation, activation, and inflammatory functions. We review the pre-clinical evidence for beneficial effects of cannabinoid drugs in a range of vascular and cardiovascular pathologies. We also discuss the clinically relevant potential of cannabinoids.

Authors+Show Affiliations

Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand. john.ashton@stonebow.otago.ac.nzNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17627561

Citation

Ashton, John C., and Paul F. Smith. "Cannabinoids and Cardiovascular Disease: the Outlook for Clinical Treatments." Current Vascular Pharmacology, vol. 5, no. 3, 2007, pp. 175-85.
Ashton JC, Smith PF. Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr Vasc Pharmacol. 2007;5(3):175-85.
Ashton, J. C., & Smith, P. F. (2007). Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Current Vascular Pharmacology, 5(3), pp. 175-85.
Ashton JC, Smith PF. Cannabinoids and Cardiovascular Disease: the Outlook for Clinical Treatments. Curr Vasc Pharmacol. 2007;5(3):175-85. PubMed PMID: 17627561.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoids and cardiovascular disease: the outlook for clinical treatments. AU - Ashton,John C, AU - Smith,Paul F, PY - 2007/7/14/pubmed PY - 2007/8/3/medline PY - 2007/7/14/entrez SP - 175 EP - 85 JF - Current vascular pharmacology JO - Curr Vasc Pharmacol VL - 5 IS - 3 N2 - Cannabinoid drugs exert their effects primarily through activation of cannabinoid CB1 and CB2 receptors. Both CB1 and CB2 receptors have been implicated in a number of cardiovascular processes, including vasodilation, cardiac protection, modulation of the baroreceptor reflex in the control of systolic blood pressure, and inhibition of endothelial inflammation and the progress of atherosclerosis in a murine model. These effects are mainly mediated through central and peripheral nervous system CB1 receptors, vascular CB1 receptors and immune cell CB2 receptors. Relevant cellular effects include: the inhibition of neurotransmitter release in the nucleus tractus solitarius and in peripheral adrenergic neurons; regulation of NOS activity in vascular beds; inhibition of vascular smooth muscle cell excitability; regulation of endothelial cell migration and proliferation; and effects on immune cell proliferation, activation, and inflammatory functions. We review the pre-clinical evidence for beneficial effects of cannabinoid drugs in a range of vascular and cardiovascular pathologies. We also discuss the clinically relevant potential of cannabinoids. SN - 1570-1611 UR - https://www.unboundmedicine.com/medline/citation/17627561/abstract/Cannabinoids_and_cardiovascular_disease:_the_outlook_for_clinical_treatments L2 - http://www.eurekaselect.com/78460/article DB - PRIME DP - Unbound Medicine ER -